Biogen’s hopes that one of its established multiple sclerosis drugs might also help stroke sufferers have been dashed. Natalizumab – best known as MS drug Tysabri - failed to show any benefits ...

Biogen’s CEO Chris Vibacher said ‘a new Biogen’ is emerging following the end of its multiple sclerosis treatments heyday.

Biotech company Biogen (NASDAQ:BIIB) beat Wall Street’s revenue expectations in Q1 CY2025, with sales up 6.1% year on year to ...

Biogen stock was muted Thursday after the biotech company beat Wall Street's first-quarter expectations, including strong sales for newcomer drugs Leqembi and Skyclarys.Leqembi, which partner Eisai ...

Biogen beat Q1 earnings and revenue estimates, raised rare disease drug sales, and cut its 2025 EPS guidance due to a $165 million collaboration payment.

Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts" report has been added to ResearchAndMarkets.com's offering.This Tysabri (natalizumab) market report delivers an ...

Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers ...

Biogen Inc.'s earnings and share price have ... This includes their products Tysabri, Tecfidera, Vumerity, Avonex, Plegridy and Fampyra, alongside some MS treatments for which they receive ...

In the first quarter, lower sales of multiple sclerosis (“MS”) drugs are likely to have been offset by revenues from new drugs. Sales of Biogen’s MS drugs like Tecfidera and Tysabri are ...